image of T. Ayers Pelz

T. Ayers Pelz

... Unknown

Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring …